tiprankstipranks
Trending News
More News >
Response Genetics (RGDXQ)
OTHER OTC:RGDXQ
US Market

Response Genetics (RGDXQ) Price & Analysis

Compare
8 Followers

RGDXQ Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

15.47%84.53%
Insiders
15.47% Other Institutional Investors
84.53% Public Companies and
Individual Investors

RGDXQ FAQ

What was Response Genetics’s price range in the past 12 months?
Response Genetics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
    What is Response Genetics’s market cap?
    Response Genetics’s market cap is $39.00.
      When is Response Genetics’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Response Genetics’s earnings last quarter?
      Currently, no data Available
      Is Response Genetics overvalued?
      According to Wall Street analysts Response Genetics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Response Genetics pay dividends?
        Response Genetics does not currently pay dividends.
        What is Response Genetics’s EPS estimate?
        Response Genetics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Response Genetics have?
        Response Genetics has 38,795,000 shares outstanding.
          What happened to Response Genetics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Response Genetics?
          Currently, no hedge funds are holding shares in RGDXQ

          Company Description

          Response Genetics

          Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
          Similar Stocks
          Company
          Price & Change
          Follow
          Precipio
          BioNano Genomics
          Intelligent Bio Solutions
          Mainz Biomed B.V.
          bioAffinity Technologies, Inc.
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis